Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer

Inclusion Criteria:

   - Histologically confirmed invasive thymoma or thymic carcinoma, meeting the following
   criteria:

      - Relapsed or refractory disease

      - Metastatic, unresectable disease

      - Locally invasive disease allowed provided it is not resectable and has been
      previously treated

      - Progressive disease

   - Measurable disease, defined as >= 1 unidimensionally measurable lesion >= 20 mm by
   conventional techniques or >= 10 mm by spiral CT scan

   - Must have received >= 1 prior chemotherapy regimen

   - No active brain metastases

   - Patients with previously treated brain metastases (surgical resection or radiotherapy)
   are eligible provided they have documented stable brain disease for >= 1 month after
   completion of therapy and are asymptomatic

   - ECOG performance status 0-2

   - Leukocytes >= 3,000/mm^3

   - ANC >= 1,500/mm^3

   - Platelet count >= 100,000/mm^3

   - Hemoglobin > 9 g/dL

   - Serum bilirubin < 2.0 times upper limit of normal (ULN)

   - Transaminases =< 2.5 times ULN (< 5.0 times ULN if liver metastasis is present)

   - Serum creatinine < 1.5 times ULN OR creatinine clearance > 50 mL/min

   - Urine protein:creatinine ratio < 0.5 OR urine protein < 1,000 mg by 24-hour urine
   collection

   - QTc < 460 msec

   - Not pregnant or nursing

   - Negative pregnancy test

   - Fertile patients must use effective contraception during and for 30 days after
   completion of study treatment

   - No known history of allergic reactions attributed to compounds of similar chemical or
   biological composition to AZD0530

   - No other malignancies within the past 3 years, except curatively treated in situ
   carcinoma of the cervix or completely resected nonmelanoma skin cancer

   - No concurrent active malignancies other than thymic malignancy

   - No condition that impairs the ability to swallow AZD0350 tablets (e.g.,
   gastrointestinal tract disease resulting in an inability to take oral medication or a
   requirement for IV alimentation, prior surgical procedures affecting absorption, or
   active peptic ulcer disease)

   - No cardiac dysfunction including, but not limited to, any of the following:

      - Symptomatic congestive heart failure

      - Unstable angina pectoris

      - Cardiac arrhythmia

      - History of ischemic heart disease

      - Myocardial infarction within the past year

      - No QTc prolongation or other significant ECG abnormalities

      - No poorly controlled hypertension (i.e., systolic blood pressure [BP] ≥ 150 mm Hg
      or diastolic BP ≥ 95 mm Hg)

   - No evidence of severe or uncontrolled systemic conditions that would make it
   undesirable to participate in the study or that would jeopardize compliance with the
   study, including any of the following:

      - Severe hepatic impairment

      - Interstitial lung disease (bilateral, diffuse, or parenchymal lung disease)

      - Unstable or uncompensated respiratory condition

      - Unstable or uncompensated cardiac condition

   - No uncontrolled illness including, but not limited to, any of the following:

      - Ongoing or active infection

      - Mental health issues or social circumstances that would limit compliance with
      study requirements

   - No prior src inhibitors

   - At least 4 weeks since prior systemic therapy (6 weeks for carmustine or mitomycin C)

   - At least 8 weeks since prior immunotherapy

   - At least 4 weeks since prior octreotide

   - Concurrent octreotide for pure red cell aplasia allowed provided patient continues on
   the same dose and schedule, has had a response to this drug, and has demonstrated
   progressive thymoma by radiography or physical exam

   - At least 4 weeks since prior surgery and recovered

   - At least 4 weeks since prior investigational agents

   - At least 4 weeks since prior radiotherapy to measurable disease sites (2 weeks for
   palliative radiotherapy to metastatic sites) and recovered

   - At least 7 days since prior and no concurrent active CYP3A4 agents or substances

   - No other concurrent investigational or anticancer agents

   - No concurrent combination antiretroviral therapy for HIV-positive patients

   - Concurrent steroids allowed for treatment of a pre-existing autoimmune disorder or as
   antiemetic therapy